MK2 Inhibitor Solid Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate in effectively targeting protein kinase-mediated diseases, such as inflammatory and autoimmune disorders, due to limitations in inhibiting specific kinases like MK2, which are involved in various inflammatory processes.
Innovation Solution
Development of novel solid forms of a compound, including salt forms, freebase forms, and complexes, that act as inhibitors of MK2 kinases, offering improved aqueous solubility, stability, and ease of formulation, thereby effectively treating or lessening the severity of associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to target protein kinase-mediated diseases, then treatment is provided, but the agents are inadequate in effectively inhibiting specific kinases like MK2
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of the compound to achieve optimal binding affinity and selectivity for MK2 kinase. The solid form development optimizes physical parameters such as solubility and stability while maintaining the biochemical parameters of kinase inhibition effectiveness and specificity.
2Ease of manufacture
If novel solid forms of the compound are developed to improve aqueous solubility and stability, then formulation ease is enhanced, but the complexity of developing multiple solid forms increases
Solution Approach 1:
The patent applies parameter changes by systematically exploring different solid forms (salts, solvates, hydrates, polymorphs) to optimize physical properties. Each solid form represents a different crystalline arrangement or chemical association that modifies solubility, stability, and manufacturability parameters while maintaining the core pharmacological activity.
Solution Approach 2:
The patent utilizes composite materials by creating salt forms and solvates that combine the parent compound with various counterions or solvent molecules. These composite solid forms leverage the properties of both components to achieve improved solubility, stability, and formulation characteristics.
3Reliability
If the compound is designed for potent MK2 inhibition, then therapeutic benefit is achieved, but the compound may have poor solubility and stability
Solution Approach 1:
The patent resolves this contradiction by changing the physical state and chemical form of the compound through solid form development. By creating different salts, solvates, hydrates, and polymorphs, the patent optimizes solubility and stability parameters without altering the core molecular structure responsible for MK2 inhibition activity.
Solution Approach 2:
The patent introduces intermediary substances such as counterions in salt forms and solvent molecules in solvates to mediate between the potent but poorly soluble/stable parent compound and the desired therapeutic outcome. These intermediaries improve physical properties while the active compound maintains its kinase inhibitory function.
Data Source
AI summary
The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.